In the letter regarding the mCRC trial Dr. L says:
Post# of 148831
"The Data and Safety Monitoring Board (DSMB) will perform a second safety review after the first 20 patients have completed at least 1 cycle of therapy."
I checked the protocol on Clinical Trials.gov and couldn't see anything that defined what "1 cycle of therapy" is. Does anyone know what that means? I'm very curious because that's when the DSMB would do an important review of safety (and possibly, efficacy).